PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.
|Articles|June 14, 2016
Fast Dissolve Oral Dosing of Macromolecules
Advertisement
Catalent's Zydis® orally disintegrating tablet (ODT) fast-dissolve formulation is a unique, freeze-dried oral dosage form that disperses instantly in the mouth, requiring no water.
With more than 20 products launched in 50 countries, Zydis is the world's best in class ODT technology. Whether to advance pharmacokinetics through pre-gastric absorption, potentially improve patient compliance, or add marketing advantage to a valued brand, Catalent's customers draw on Zydis fast dissolve technology to potentially enhance investment value and accelerate a product's potential.
Catalent has now expanded the Zydis technology platform to overcome traditional oral delivery challenges of large molecules such as proteins, peptides, viral vaccines and allergens. Zydis Bio has the potential to deliver fast-dissolve formulations of such therapies in a patient preferred oral fast dissolve dose form, in as little as three seconds.
Catalent. more products. better treatments. reliably suppliedâ¢
Contact Details :
Catalent Pharma Solutions
Website:
E-mail:
Advertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
2
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
3
PharmTech AI Pulse Check: Availability Bias Threatens AI Regulatory Reviews
4
Symptomatic Dermographism: Novartis Lands Remibrutinib Label Expansion
5